Trials / Completed
CompletedNCT00772980
Efficacy, Safety and Tolerability of Neramexane in Comparison to Placebo in Patients With Subjective Tinnitus
A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- Merz Pharmaceuticals GmbH · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of subjective tinnitus in comparison to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Neramexane mesylate | Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day, 12 weeks follow-up. |
| DRUG | Placebo | Double-blind treatment period of 17 weeks placebo, 12 weeks follow-up. |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2008-10-15
- Last updated
- 2010-07-01
Locations
56 sites across 6 countries: Belgium, Czechia, France, Netherlands, Poland, South Africa
Source: ClinicalTrials.gov record NCT00772980. Inclusion in this directory is not an endorsement.